Kbi-110 ((new)) Jun 2026

KBI-110 is likely in . Early data focuses on dose escalation: finding the sweet spot where efficacy is high but cytokine release syndrome (CRS) is low.

The truth, much like the entity itself, remains shrouded in mystery. KBI-110

Regulatory agencies have been cautious with epigenetic drugs due to historic concerns about on‑target toxicity (e.g., hematologic suppression). Demonstrating reversible pharmacology and a clear therapeutic window will be essential. KBI-110 is likely in